Next Generation of CAR-T Therapies in Lymphoma
Experts comment on the future of CAR T-cell therapy development and the use of dual CAR-T and CAR-T retreatment.
Future Perspectives on CAR-T Therapies in Lymphoma
Drs Goy, Ip, and Leslie close out their discussion with a look at the exciting developments and future of CAR T-cell therapies in lymphoma treatment.
Selecting and Sequencing Therapies to Improve Outcomes in Patients With Lymphoma
Key opinion leaders describe when to refer a patient with lymphoma and at what point treatments should be switched, and the evolution of T-cell engaging therapies.
Recent Updates on CAR-T Therapies in Chronic Lymphocytic Leukemia
Dr Lori Leslie provides an overview of key clinical trial data on the use of CAR T-cell therapy in chronic lymphocytic leukemia.
Role of CAR-T Therapies in Acute Lymphoblastic Lymphoma
Drs Goy and Leslie converse on the use of CAR T-cell therapy in acute lymphoblastic lymphoma, the first approved treatment for ALL.
CAR-T Therapies in the Follicular Lymphoma Treatment Landscape
Lori Leslie, MD, explains how CAR T-cell therapy fits into follicular lymphoma treatment sequencing, highlighting data from the ZUMA-5 trial.
Brexucabtagene Autoleucel in Mantle Cell Lymphoma
Andre Goy, MD, and Andrew Ip, MD, give an overview of the approval of CAR T-cell therapy for mantle cell lymphoma treatment.
Managing Toxicities Associated with CAR-T Therapy in LBCL
Dr Andrew Ip explains the major toxicities of CAR T-cell therapy in patients with large B-cell lymphoma and how to manage them.
CAR-T therapy in Second-Line Setting in LBCL
Lymphoma physicians from John Theurer Cancer Center comment on the use of CAR T-cell therapy in large B-cell lymphoma and the implications of clinical trial data in this setting.
Selecting the Appropriate Patients and Monitoring Responses to CAR T-Cell Therapy in LBCL
Dr Lori Leslie discusses how to assess if a patient with large B-cell lymphoma is a good candidate for CAR T-cell therapy.
Clinical Trial and Real-World Evidence Around CAR T-cell Therapy in LBCL
Andrew Ip, MD, and Lori Leslie, MD, review clinical trial and real-world data on the efficacy and survival rates of CAR T-cell therapy in large B-cell lymphoma.
Lori Leslie, MD, Discusses the Real-World Differences Between Acalabrutinib and Ibrutinib
The medical oncologist from the John Theurer Cancer Center noted the importance of real-world data in determining potentially different toxicity profiles in these BTK-inhibitors.
Lori Leslie, MD, Discusses CAR T-cell therapy and DLBCL